Bladder tumor treatment, viral nanoparticle conjugates, immune therapy

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted patent US12589165B2 to the Department of Health and Human Services covering methods for treating bladder tumors using viral nanoparticle conjugates combined with immune checkpoint inhibitors. The patent, with inventors including John Todd Schiller and Rhonda C. Kines, contains 20 claims and was filed on April 11, 2018. This represents a technology transfer of government-funded research to advance immunotherapy treatment options.

View original document View source feed page

What changed

The USPTO issued Patent No. US12589165B2 to the United States of America (represented by the Secretary of the Department of Health and Human Services) for methods and compositions treating tumors using immunotherapeutic agents combined with tumor-targeting viral capsid protein assemblages. The patent covers anti-cancer molecules conjugated to viral capsid proteins. Key inventors include Elisabet de los Pinos, John Todd Schiller, and Rhonda C. Kines, with 20 claims granted.

Pharmaceutical and biotechnology companies developing immunotherapies, viral nanoparticle cancer treatments, or bladder cancer therapeutics should review this patent to assess potential overlap with their research programs. No immediate compliance action is required for this patent grant notice. Parties interested in licensing this technology should contact the National Institutes of Health Office of Technology Transfer.

Source document (simplified)

← USPTO Patent Grants

Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors

Grant US12589165B2 Kind: B2 Mar 31, 2026

Assignee

The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventors

Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines

Abstract

Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.

CPC Classifications

A61K 47/6901 A61K 39/3955 A61K 41/0061 A61K 41/0071 A61K 41/0076 A61K 2039/54 A61K 2039/545 A61K 39/39558 A61K 45/06 A61K 47/62 A61K 39/395 A61P 35/00 C12N 7/00 C12N 2710/20023 C12N 2710/20042 C12N 2710/20071 C07K 16/2818 C07K 16/2827 B82Y 5/00